glyburide has been researched along with Carotid Artery Diseases in 7 studies
Glyburide: An antidiabetic sulfonylurea derivative with actions like those of chlorpropamide
glyburide : An N-sulfonylurea that is acetohexamide in which the acetyl group is replaced by a 2-(5-chloro-2-methoxybenzamido)ethyl group.
Carotid Artery Diseases: Pathological conditions involving the CAROTID ARTERIES, including the common, internal, and external carotid arteries. ATHEROSCLEROSIS and TRAUMA are relatively frequent causes of carotid artery pathology.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We compared the effects of two insulin secretagogues, repaglinide and glyburide, known to have different efficacy on postprandial hyperglycemia, on carotid intima-media thickness (CIMT) and markers of systemic vascular inflammation in type 2 diabetic patients." | 5.11 | Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus. ( Esposito, K; Giugliano, D; Marfella, R; Nappo, F, 2004) |
| "Metformin is a well-known oral hypoglycaemic agent and has been commonly used, in combination with sulphonylurea, to treat type 2 diabetes." | 2.71 | Metformin or gliclazide, rather than glibenclamide, attenuate progression of carotid intima-media thickness in subjects with type 2 diabetes. ( Hayaishi-Okano, R; Hori, M; Kaneto, H; Katakami, N; Kosugi, K; Matsuhisa, M; Ohtoshi, K; Yamasaki, Y, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (14.29) | 18.2507 |
| 2000's | 3 (42.86) | 29.6817 |
| 2010's | 1 (14.29) | 24.3611 |
| 2020's | 2 (28.57) | 2.80 |
| Authors | Studies |
|---|---|
| Sposito, AC | 2 |
| Breder, I | 2 |
| Soares, AAS | 2 |
| Kimura-Medorima, ST | 2 |
| Munhoz, DB | 2 |
| Cintra, RMR | 1 |
| Bonilha, I | 1 |
| Oliveira, DC | 1 |
| Breder, JC | 1 |
| Cavalcante, P | 1 |
| Moreira, C | 1 |
| Moura, FA | 1 |
| de Lima-Junior, JC | 1 |
| do Carmo, HRP | 1 |
| Barreto, J | 2 |
| Nadruz, W | 2 |
| Carvalho, LSF | 1 |
| Quinaglia, T | 2 |
| Wolf, VLW | 1 |
| de Carvalho, LSF | 1 |
| Cintra, RM | 1 |
| Guerra-Júnior, G | 1 |
| Muscelli, E | 1 |
| Katakami, N | 2 |
| Kaneto, H | 2 |
| Matsuhisa, M | 2 |
| Shimomura, I | 1 |
| Yamasaki, Y | 2 |
| Matsumoto, K | 1 |
| Sera, Y | 1 |
| Abe, Y | 1 |
| Tominaga, T | 1 |
| Yeki, Y | 1 |
| Miyake, S | 1 |
| Esposito, K | 1 |
| Giugliano, D | 1 |
| Nappo, F | 1 |
| Marfella, R | 1 |
| Hayaishi-Okano, R | 1 |
| Ohtoshi, K | 1 |
| Kosugi, K | 1 |
| Hori, M | 1 |
| Faraci, FM | 1 |
| Orgren, K | 1 |
| Heistad, DD | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| FLAT-SUGAR: FLuctuATion Reduction With inSULin and Glp-1 Added togetheR[NCT01524705] | Phase 4 | 102 participants (Actual) | Interventional | 2012-08-31 | Completed | ||
| Variability of Glucose Assessed in a Randomized Trial Comparing the Initiation of A Treatment Approach With Biosimilar Basal Insulin Analog Or a Titratable iGlarLixi combinatioN in Type 2 Diabetes Among South Asian Subjects (VARIATION 2 SA Trial)[NCT03819790] | Phase 4 | 119 participants (Actual) | Interventional | 2018-10-02 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The change in the coefficient of variation (CV) of continuous glucose readings, as assessed by Continuous Glucose Monitoring (CGM) (NCT01524705)
Timeframe: At baseline, 6 months of intervention
| Intervention | percentage (Mean) |
|---|---|
| Insulin Glargine, Metformin, Exenatide | -2.43 |
| Insulin Glargine, Metformin, Prandial Insulin | 0.44 |
% of glycosylated hemoglobin in whole blood at 26 weeks (NCT01524705)
Timeframe: Baseline vs 26 weeks
| Intervention | % of HbA1C (Mean) |
|---|---|
| Insulin Glargine, Metformin, Exenatide | 7.1 |
| Insulin Glargine, Metformin, Prandial Insulin | 7.2 |
Severe hypoglycemia-documented glucose <50mg/dl (participant journal), and hypoglycemic attacks requiring hospitalization, or treatment by emergency personnel. (NCT01524705)
Timeframe: 26 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Insulin Glargine, Metformin, Exenatide | 0 |
| Insulin Glargine, Metformin, Prandial Insulin | 0 |
Weight in kg at 26 weeks minus weight at baseline. (NCT01524705)
Timeframe: Baseline vs 26 weeks
| Intervention | kg (Mean) |
|---|---|
| Insulin Glargine, Metformin, Exenatide | -4.8 |
| Insulin Glargine, Metformin, Prandial Insulin | 0.7 |
4 trials available for glyburide and Carotid Artery Diseases
| Article | Year |
|---|---|
Dapagliflozin effect on endothelial dysfunction in diabetic patients with atherosclerotic disease: a randomized active-controlled trial.
Topics: Adult; Aged; Benzhydryl Compounds; Biomarkers; Blood Glucose; Brazil; Carotid Artery Diseases; Diabe | 2021 |
Dapagliflozin increases the lean-to total mass ratio in type 2 diabetes mellitus.
Topics: Absorptiometry, Photon; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Body Composition; Body Wei | 2021 |
Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus.
Topics: Adult; Aged; Biomarkers; Blood Glucose; Carbamates; Carotid Artery Diseases; Cross-Sectional Studies | 2004 |
Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus.
Topics: Adult; Aged; Biomarkers; Blood Glucose; Carbamates; Carotid Artery Diseases; Cross-Sectional Studies | 2004 |
Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus.
Topics: Adult; Aged; Biomarkers; Blood Glucose; Carbamates; Carotid Artery Diseases; Cross-Sectional Studies | 2004 |
Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus.
Topics: Adult; Aged; Biomarkers; Blood Glucose; Carbamates; Carotid Artery Diseases; Cross-Sectional Studies | 2004 |
Metformin or gliclazide, rather than glibenclamide, attenuate progression of carotid intima-media thickness in subjects with type 2 diabetes.
Topics: Carotid Arteries; Carotid Artery Diseases; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fem | 2004 |
3 other studies available for glyburide and Carotid Artery Diseases
| Article | Year |
|---|---|
Effects of glimepiride and glibenclamide on carotid atherosclerosis in type 2 diabetic patients.
Topics: Aged; Carotid Artery Diseases; Diabetes Mellitus, Type 2; Female; Glyburide; Humans; Hypoglycemic Ag | 2011 |
Metformin attenuates progression of carotid arterial wall thickness in patients with type 2 diabetes.
Topics: Arteriosclerosis; Carotid Arteries; Carotid Artery Diseases; Chronic Disease; Diabetes Mellitus, Typ | 2004 |
Impaired relaxation of the carotid artery during activation of ATP-sensitive potassium channels in atherosclerotic monkeys.
Topics: Acetylcholine; Adenosine Triphosphate; Animals; Arteriosclerosis; Carotid Arteries; Carotid Artery D | 1994 |